{
    "id": 712,
    "name": "refractory hematologic cancer",
    "source": "DOID",
    "definition": "A hematologic cancer that is located in the blood or bone marrow that doesn't respond to treatment. [url:http\\://www.cancer.gov/dictionary/?CdrID=45708, url:http\\://www.cancer.gov/templates/db_alpha.aspx?CdrID=45863]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:712",
    "evidence": [
        
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01943851",
            "title": "A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 784,
                    "therapyName": "GSK525762",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02240719",
            "title": "Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2336,
                    "therapyName": "Bendamustine + Everolimus",
                    "synonyms": null
                }
            ]
        }
    ]
}